報價延遲最少15分鐘:2026/05/31 07:50 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.06 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-13.82/-1.79
|
|
企業價值
13.09M
|
| 資產負債 |
|
每股賬面淨值
0.09
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
2.49M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials. |
